VNDA Vanda: Forward Price-to-Revenue Multiple

Public company logo of vandapharma.com (VNDA)

Vanda Pharmaceuticals (VNDA) adheres to standard environmental regulations regarding the disposal of laboratory waste. The issuer's forward P/S reflects the valuation dynamics of expected sales, while the 1.00 level captures recent values. The asset relies on robust R&D potential in CNS therapy, and the ownership of exclusive medications for schizophrenia and insomnia creates a protected market niche.

Vanda Pharmaceuticals Inc. - VNDA Forward P/S Multiple (period 07/04/2022 - 11/13/2026)

Vanda - analytical breakdowns and key metrics (VNDA)

- market price and analyst price targets:
Price Chart Vanda Pharmaceuticals Inc.|VNDA - Average Forecast Price
- company stock capitalization data:
Market Valuation Vanda|VNDA - Total Company Value
- business book valuation details:
Book Value per Share Vanda Pharmaceuticals|VNDA - Book Capitalization|Market Value to Book Value Ratio vandapharma.com|VNDA - Total Business Assets
- business debt structure and liquidity details:
Total Debt to Capital Vanda Pharmaceuticals|VNDA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Vanda Pharmaceuticals|VNDA - Company Aggregate Debts|Debt to Book Value Vanda|VNDA - Company Long-Term Loans and Borrowings|Company Short-Term Debt Vanda Pharmaceuticals|Quick Ratio vandapharma.com
- financial results and valuation multiples details:
VNDA - Final Profit|Projected Future Earnings Vanda Pharmaceuticals|VNDA - P/E Multiple|Future Price to Earnings Vanda Pharmaceuticals Inc|VNDA - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vanda|VNDA - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Vanda Pharmaceuticals|VNDA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth vandapharma.com|VNDA - Net earnings per share growth this year|Earnings growth forecast for next year Vanda Pharmaceuticals
- total revenue and sales volume data:
VNDA - Company Total Revenue|Company Future Sales Volume Vanda Pharmaceuticals Inc.|VNDA - P/S Multiple|Forward Price-to-Revenue Multiple Vanda
Fundamental company analysis:Vanda Pharmaceuticals Inc. (VNDA)
Product sample of Vanda

Vanda Pharmaceuticals (VNDA) maintains a strong scientific reputation in the therapy of complex psychoneurological disorders, rendering its revenue dependent on the trust of the medical community. By analyzing the forward P/S ratio, an investor determines the cost of one dollar of expected sales to avoid overpaying for unfounded hopes and to accurately assess the asset's market balance relative to the company's future cash flows.

Key competitors

Price-to-Projected Revenue Ratio Alkermes ALKS|Avadel Pharmaceuticals PLC (AVDL) - Market Cap to Future Revenue Ratio|ATAI: Forward Price-to-Revenue Multiple|GHRS: Price-to-Projected Revenue Ratio|MNMD: Forward P/S Multiple|compasspathways.com (CMPS) - Forward P/S Multiple|Price-to-Projected Revenue Ratio LB Pharmaceuticals|Market Cap to Projected Revenue DRUG (Bright Minds Bio)|Forward P/S Multiple CYBN|Alto Neuroscience Corp - Market Cap to Projected Revenue|Forward P/S Multiple NRXP (NRx Pharmaceuticals)|Forward P/S Multiple Cingulate Inc CING|SILO: Forward Price-to-Revenue Multiple|Forward Price to Sales CPHI (China Pharma Holdings)|Clearmind Medicine (CMND) - Price-to-Projected Revenue Ratio|Future Price to Revenue PBM (Psyence Bio)|SPRC (SciSparc Ltd) - Forward P/S Multiple|SEEL: Forward Price to Sales|Forward P/S Multiple VRPX|Forward P/S Multiple Karuna Therapeutics Inc (KRTX)